Page last updated: 2024-11-12
2,5-dimethylcelecoxib
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
2,5-dimethylcelecoxib: non-COX-2 inhibitory structural analog of celecoxib [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 11545682 |
| CHEMBL ID | 2163630 |
| SCHEMBL ID | 2228663 |
| MeSH ID | M0493627 |
Synonyms (26)
| Synonym |
|---|
| 2,5-dimethylcelecoxib |
| 2,5-dimethyl-celecoxib |
| 4-[5-(2,5-dimethylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide |
| 457639-26-8 |
| 4-(5-(2,5-dimethylphenyl)-3-(trifluoromethyl)-1h-pyrazol-1-yl)benzenesulfonamide |
| dimethyl celecoxib |
| CHEMBL2163630 |
| 4-[5-(2,5-dimethylphenyl)-3-(trifluoromethyl)-1h-pyrazol-1-yl]-benzenesulfonamide |
| SCHEMBL2228663 |
| HB3717 |
| c18h16f3n3o2s |
| 2,5-dimethyl celecoxib |
| DTXSID00196614 |
| 2,5-dimethyl-celecoxib, vetranal(tm), analytical standard |
| 2,5-dimethyl-celecoxib, >=98% (hplc) |
| AKOS027475480 |
| 4-[5-(2,5-dimethylphenyl)-3-(trifluoromethyl)-1h-pyrazol-1-yl]benzenesulfonamide |
| NCGC00485044-01 |
| BCP08101 |
| FT-0667393 |
| 2,5-dimethyl celecoxib, dmc |
| CCG-357033 |
| benzenesulfonamide, 4-[5-(2,5-dimethylphenyl)-3-(trifluoromethyl)-1h-pyrazol-1-yl]-; 4-[5-(2,5-dimethylphenyl)-3-(trifluoromethyl)-1h-pyrazol-1-yl]benzenesulfonamide |
| 2,5-dimethylcelecoxib 100 microg/ml in acetonitrile |
| ntfosuuwgcdxef-uhfffaoysa-n |
| 2,5-dimethylcelecoxib-d4 |
Research Excerpts
Compound-Compound Interactions
| Excerpt | Reference | Relevance |
|---|---|---|
| " We propose that this novel drug combination should receive further evaluation as a potentially effective anticancer therapy." | ( Aggravated endoplasmic reticulum stress as a basis for enhanced glioblastoma cell killing by bortezomib in combination with celecoxib or its non-coxib analogue, 2,5-dimethyl-celecoxib. Chen, TC; Golden, EB; Hofman, FM; Kardosh, A; Louie, SG; Petasis, NA; Pyrko, P; Schönthal, AH; Uddin, J, 2008) | 0.35 |
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (7)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1347160 | Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347159 | Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID697540 | Binding affinity to mouse recombinant CDH11 extracellular domain 1-2 by surface plasmon resonance | 2012 | Journal of medicinal chemistry, Aug-09, Volume: 55, Issue:15 | Predicting new indications for approved drugs using a proteochemometric method. |
| AID697539 | Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTS assay | 2012 | Journal of medicinal chemistry, Aug-09, Volume: 55, Issue:15 | Predicting new indications for approved drugs using a proteochemometric method. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (41)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (26.83) | 29.6817 |
| 2010's | 19 (46.34) | 24.3611 |
| 2020's | 11 (26.83) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 10.99
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (10.99) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 3 (7.14%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 39 (92.86%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||